Mehran Score for Post-PCI Contrast Nephropathy

Predicts risk of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI). Mehran Scoreshould be used in patients undergoing PCI.
NB! Do not use in patients with pre-existing end-stage renal disease on dialysis or patients with contrast exposure within 1 week of the index procedure.
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
≥ 60
40 to < 60
20 to < 40
<20
Patient’s Score | CIN Risk Score | Risk of any post-PCI CIN | Risk of post-PCI CIN requiring dialysis |
---|---|---|---|
0 | 0 | 0 | 0 |
Hypotension (SBP <80 for ≥1 hr requiring inotrope or balloon pump within 24 hrs of cath) | +5 |
Intra-aortic balloon pump | +5 |
Congestive heart failure (CHF class III/IV by New York Heart Association Classification and/or history of pulmonary edema) | +5 |
Age >75 years | +4 |
Anemia (Baseline hematocrit value <39% for men and <36% for women) | +3 |
Diabetes | +3 |
Contrast Media Volume | 1 pt./100 mL contrast |
eGFR, mL/min/1.73 m² | |
≥60 | 0 |
40 to <60 | +2 |
20 to <40 | +4 |
<20 | +6 |
Interpretation:
CIN Risk Score | Risk of any post-PCI CIN | Risk of post-PCI CIN requiring dialysis |
≤5 | 7.5% | 0.04% |
6-10 | 14.0% | 0.12% |
11-15 | 26.1% | 1.09% |
≥16 | 57.3% | 12.6% |
In the original study, “contrast-induced nephropathy” was defined as an increase ≥0.5 mg/dL (or ≥25%) in pre-PCI serum creatinine at 48 hours post-PCI.
Consider renal protective measures such as N-acetylcysteine and limiting contrast volume in patients at high risk of CIN.
References:
- Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-9. https://doi.org/10.1016/j.jacc.2004.06.068
- Sgura FA, Bertelli L, Monopoli D, Leuzzi C, Guerri E, Spartà I, Politi L, Aprile A, Amato A, Rossi R, Biondi-Zoccai G, Sangiorgi GM, Modena MG. Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 2010 Oct;3(5):491-8. doi: 10.1161/CIRCINTERVENTIONS.110.955310. Epub 2010 Oct 5. PMID: 20923986.
- Bonnie Raingruber, Holly Kirkland-Walsh, Nikky Chahon, Michael Kellermann; Using the Mehran Risk Scoring Tool to Predict Risk for Contrast Medium–Induced Nephropathy in Patients Undergoing Percutaneous Angiography. Crit Care Nurse 1 February 2011; 31 (1): e17–e22. doi: https://doi.org/10.4037/ccn2011746
- Wi J, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, Ha JW, Hong MK, Jang Y. Prediction of Contrast-Induced Nephropathy With Persistent Renal Dysfunction and Adverse Long-term Outcomes in Patients With Acute Myocardial Infarction Using the Mehran Risk Score. Clin Cardiol. 2013 Jan;36(1):46-53. doi: 10.1002/clc.22060. Epub 2012 Oct 1. PMID: 23027701; PMCID: PMC6649613.
- Abellás-Sequeiros RA, Raposeiras-Roubín S, Abu-Assi E, González-Salvado V, Iglesias-Álvarez D, Redondo-Diéguez A, González-Ferreiro R, Ocaranza-Sánchez R, Peña-Gil C, García-Acuña JM, González-Juanatey JR. Mehran contrast nephropathy risk score: Is it still useful 10 years later? J Cardiol. 2016 Mar;67(3):262-7. doi: 10.1016/j.jjcc.2015.05.007. Epub 2015 Jul 10. PMID: 26169247.
Register on our website right now to have access to more learning materials!
Charlson Comorbidity Index (CCI) Online Calculator
Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.
Multiple Myeloma Diagnostic Criteria – Online Calculator
Revised Multiple Myeloma International Staging System (R-ISS) Online Calculator
Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on…
Multiple Myeloma International Staging System (ISS) Online Calculator
Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely…
SAVED VTE Score
SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…
IMPEDE VTE Score
IMPEDE score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…